Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.74
+0.24 (3.13%)
At close: Sep 30, 2026, 4:00 PM EDT
8.01
+0.27 (3.56%)
Pre-market: Oct 1, 2026, 4:06 AM EDT
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$1,287,398
Profits / Employee
$37,805
Market Cap
505.76M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| REGENXBIO | 371 |
| ProKidney | 231 |
| Puma Biotechnology | 179 |
| Assembly Biosciences | 73 |
| AgomAb Therapeutics NV | 62 |
| Contineum Therapeutics | 51 |
| Bright Minds Biosciences | 26 |
ARVN News
- 1 day ago - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723 - TheFly
- 2 days ago - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate - GlobeNewsWire
- 14 days ago - Arvinas Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 20 days ago - Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 22 days ago - Arvinas Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 27 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Arvinas price target lowered to $10 from $11 at Morgan Stanley - TheFly